Evolent Health Q2 Earnings Call Highlights

Key Points

• Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, while adjusted EBITDA guidance narrowed to $120 million–$135 million.
• The May launch of the Highmark partnership drove a 50% sequential increase in Performance Suite revenue to $485 million. Evolent reported encouraging early clinical and provider engagement, though the medical expense ratio rose to 95% due largely to higher reserves tied to the launch.
• Evolent announced an oncology agreement expected to generate about $300 million in annualized revenue and said AI automation, cost controls and maturing contracts should support 2027 revenue growth above 25% and adjusted EBITDA of at least $150 million at the midpoint.

Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.

Chief Executive Officer Seth Blackley said the results reflected the company’s ability to execute in a changing healthcare environment. Evolent raised its full-year revenue guidance to a range of $2.6 billion to $2.7 billion, from a prior range of $2.4 billion to $2.6 billion. It also narrowed adjusted EBITDA guidance to $120 million to $135 million, compared with its previous outlook of $110 million to $140 million.

The company maintained its expectation for a full-year medical expense ratio, or MER, of approximately 93%.

Highmark Launch Drives Performance Suite Growth

Performance Suite revenue totaled $485 million in the second quarter, rising 50% from the first quarter. Chief Financial Officer Mario Ramos said the increase was driven primarily by higher membership following the Highmark launch on May 1.

Evolent’s MER was 95% during the second quarter, compared with 93% in the first quarter. Ramos said the increase was expected and largely reflected the Highmark launch and its associated higher reserves. The company also continued to see higher acuity among exchange populations, though it said its contracts include protections against changes in prevalence.

Blackley said early results from the Highmark program were encouraging, with clinical engagement rates above targets and provider engagement exceeding initial go-live expectations. The company expects greater visibility into claims performance over the next several months.

Evolent also said its Aetna partnership, which began earlier in 2026, continued to produce clinical engagement above targets, while initial claims-based performance was in line with expectations.

For the second half, Ramos said revenue in both the third and fourth quarters is expected to be meaningfully above the second-quarter level, primarily due to Performance Suite revenue. The third quarter is expected to include a full quarter of Highmark revenue and launches in several markets tied to a previously announced Performance Suite expansion.

New Oncology and Cross-Sell Agreements

The company announced an oncology Performance Suite agreement with an existing advanced-imaging client. The arrangement is expected to cover roughly 1.5 million Medicare and Medicaid lives across 11 states and is anticipated to launch by December 2026, subject to regulatory approvals.

Evolent expects the oncology contract to generate approximately $300 million in annualized revenue. Blackley said the agreement includes the company’s enhanced contractual protections used in other recent Performance Suite arrangements.

The company also expanded its relationship with a regional Blue Cross plan and former NIA customer. The customer will add products and extend existing products to additional populations using Evolent’s specialty technology and services platform. Implementations are expected during the third and fourth quarters.

While annualized revenue from that extension is expected to be less than $5 million, Blackley said Evolent expects the agreement to generate strong adjusted EBITDA and demonstrate the company’s cross-selling opportunity within its existing customer base.

Specialty technology and services revenue was $78 million, down 3% sequentially. Ramos attributed the decline to code-review scope changes related to AHIP commitments, rather than client attrition or pricing pressure. Administrative Services revenue also declined 3% to $48 million, primarily because the first quarter included a prior-year reserve true-up.

AI Automation and Cost Focus

Blackley highlighted the company’s Auth Intelligence platform, which was built on Evolent’s 2024 acquisition of Machinify. Evolent is pursuing a long-term goal of automatically approving 80% of authorization volume, while maintaining a requirement that clinicians make recommendations involving treatment changes.

More than one-third of authorization volume that previously required manual clinical review is now being evaluated through the platform, according to Blackley. Among customers where the models have been deployed, Evolent has seen auto-approval rates improve by as much as 20 percentage points. He said certain cases previously requiring days to complete can now be approved in minutes.

Auth Intelligence is scheduled for an aggressive deployment in the first quarter of 2027 as part of a major customer renewal. Management said the platform, along with expense discipline and other productivity measures, is expected to support long-term margin goals.

2027 Outlook and Capital Structure

Based on contracted revenue and completed customer renewals, Evolent expects revenue growth of more than 25% in 2027. Ramos said the outlook includes anticipated membership pressure from Medicaid work requirements, exchange attrition and client-specific market exits.

The company expects the midpoint of its 2027 adjusted EBITDA outlook to be at or above $150 million. Ramos said the outlook assumes improving Performance Suite care margins, operating-expense reductions and ongoing AI and technology investment. While growth in the capitated Performance Suite business can reduce the company’s consolidated margin percentage, he said margins within the Performance Suite business are expected to expand as contracts mature.

Evolent ended the quarter with $115.7 million in unrestricted cash and $808.3 million in net debt. The company reduced its asset-based lending revolver by $10 million to its minimum draw of $62.5 million.

Ramos said Evolent has identified several possible ways to address its 2029 debt maturities, including EBITDA growth, improved cash-flow conversion, disciplined capital allocation and potential capital-markets or strategic actions. The company expects to improve leverage ratios and its maturity profile over the next 12 to 24 months, though management said it was too early to determine the ultimate path.

About Evolent Health (NYSE:EVH)

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company's core offerings include care management solutions, population health analytics and clinical advisory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source